Navigation Links
Extremely rare mitochondrial DNA deletions associated with aging can be accurately detected with Droplet Digital PCR
Date:9/4/2013

Seattle, Wash. September 4, 2013 A study published today in Aging Cell identifies a new tool to accurately analyze extremely rare mitochondrial DNA (mtDNA) deletions associated with a range of diseases and disorders as well as aging. This approach, which relies on Droplet Digital PCR (ddPCR) technology, will help researchers explore mtDNA deletions as potential disease biomarkers.

The accumulation of mtDNA mutations is associated with aging, neuromuscular disorders, and cancer. However, methods to probe the underlying mechanisms behind this mutagenesis have been limited by their inability to accurately quantify and characterize new deletion events, which may occur at a frequency as low as one deletion event per 100 million mitochondrial genomes in normal tissue. To address these limitations, researchers at the Seattle, Washington-based Fred Hutchinson Cancer Research Center developed a ddPCR-based assay known as "Digital Deletion Detection" (3D) that allows for the high-resolution analysis of these rare deletions.

"It is incredibly difficult to study mtDNA mutations, let alone deletions, within the genome," said Dr. Jason Bielas, Assistant Member of the Public Health Sciences Division at the Fred Hutchinson Cancer Research Center and lead author of the study. "Our 3D assay shows significant improvement in specificity, sensitivity, and accuracy over conventional methods such as those that rely on real-time PCR."

Bielas added, "The increase in throughput afforded by droplet digital PCR shortened the analysis of deletion events to days compared to months using previous digital PCR methods. Without the technology, we could not have made this discovery."

At the center of the study was Bio-Rad Laboratories' QX100 ddPCR system. Using the QX100 system, Bielas and his team analyzed eight billion human brain mtDNA genomes and identified more than 100,000 genomes with a deletion. They discovered that, contrary to popular belief, the majority of the increase in mtDNA deletions was not caused by new deletions but rather by the expansion of previous deletions. They hypothesized that the expansion of pre-existing mutations should be considered as the primary factor contributing to age-related accumulation of mtDNA deletions.

How the 3D Assay Works

3D is a novel three-step process that includes enrichment for deletion-bearing molecules, single-molecule partitioning of genomes into droplets for direct quantification via ddPCR, and breakpoint characterization using next-generation sequencing.

Once the enrichment process is completed using methods previously developed by Bielas and colleagues, the concentration of molecules within the droplets is adjusted by using the QX100 system so that the majority of droplets contain no mutant genomes while a small fraction contain only one. This process allows each deletion to be amplified without bias and without introducing the artifacts that are common in qPCR.

Following amplification, deletions can be analyzed using ddPCR to determine the absolute concentration of mutated molecules. Using the relationship between droplet fluorescence and amplicon size, Bielas and his team were able to characterize the size and complexity (whether they were a result of a few clonal expansions or a large collection of random deletions) of rare mitochondrial deletions in human brain samples.

The 3D assay provides an important new tool that will allow researchers to better study the mechanisms of deletion formation and expansion, and their role in aging. Droplet digital PCR's high throughput and increased sensitivity will also allow Bielas' lab to target other low-level disease-causing mtDNA deletions in skeletal muscle, brain tissue, and blood.


'/>"/>

Contact: Ken Li
kli@chempetitive.com
312-532-4675
Chempetitive Group
Source:Eurekalert

Related biology news :

1. Extremely high estrogen levels may underlie complications of single-birth IVF pregnancies
2. Antioxidant shown to reduce blindness risk in extremely premature babies
3. Microbiologists can now measure extremely slow life
4. Oxidative stress, mitochondrial damage and neurodegenerative diseases
5. Rare mitochondrial mutations -- maybe not so rare?
6. Biologists map rare case of fitness-reducing interaction in nuclear, mitochondrial DNA
7. Mitochondrial mutations: When the cells 2 genomes collide
8. FASEB SRC announces conference: Mitochondrial Assembly & Dynamics in Health, Disease & Aging
9. Discovery of a new family of key mitochondrial proteins for the function and viability of the brain
10. Elevated levels of copper in amyloid plaques associated with neurodegeneration in mouse models of AD
11. Research breakthrough: Impaired autophagy associated with age-related macular degeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
Breaking Biology News(10 mins):
(Date:9/17/2017)... , ... September 17, 2017 , ... ... the South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational ... against the Middle East Respiratory Syndrome coronavirus (MERS-CoV). The study in Korea represents ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... launch of its CliniControl™ (CC) product portfolio, clinically-relevant starting and ancillary materials ... of human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The CliniControl product portfolio will ...
(Date:9/14/2017)... ... September 14, 2017 , ... AIM Global, the worldwide standards agency for ... won the 2017 Case Study Competition for AIDC. The award is given to ... risk” and push the adoption of automated data collection systems further. The TRACTUS ...
(Date:9/12/2017)... ... September 12, 2017 , ... PhysIQ, a Chicago-based company ... ambulatory patient monitoring and clinical trial support, earned DPharm Idol 2017 honors at ... , Launched in 2005, PhysIQ leverages artificial intelligence (AI) to empower digital ...
Breaking Biology Technology: